Alzheimer drug discovery foundation fundings

Ends on 5 February 2021

The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer’s and related dementias. We have dedicated our funding to several key areas:

• Translational research to develop new drugs and build preclinical evidence
• IND-enabling studies and early-stage clinical trials for novel and repurposed drugs
• Development and validation of plasma, CSF, neuroimaging and digital biomarkers
• Epidemiological studies and comparative effectiveness research

Applications are reviewed throughout the year through our core programs. Check back regularly for additional joint funding opportunities with our partners in non-profits, government, and industry.

CORE FUNDING PROGRAMS

NOTE: Due to the COVID-19 pandemic, we understand there may be delays in submitting applications. We will consider an extension if delays are anticipated. Please email the scientific contact listed on the relevant RFP to discuss further.

NOW ACCEPTING APPLICATIONS
Upcoming 2021 deadlines
Must be received by 5:00 pm ET on the deadline date.

Drug Development RFP
Program to Accelerate Clinical Trials (PACT) RFP
Neuroimaging and CSF Biomarker Development RFP
Prevention Pipeline RFP

ADDF/NIH Funding and SBIR/STTR Bridge Funding Opportunities

DIAGNOSTICS ACCELERATOR PROGRAMS

ACCEPTING APPLICATIONS ON A ROLLING BASIS

Learn more about the Diagnostics Accelerator here
Peripheral Biomarkers RFP
Digital Biomarkers RFP

OTHER FUNDING OPPORTUNITIES WITH OUR PARTNERS

ADDF-Harrington Scholar Program RFP (2020 deadline past, planned release spring 2021)
Accelerating Drug Discovery for FTD RFP (2020 deadline past, planned release spring 2021)
The Treat FTD RFP for Clinical Trials

NOW ACCEPTING APPLICATIONS

CONFERENCE FUNDING

Supports scientific conferences that are relevant to our mission with grants up to $10,000. For more information, email with a brief summary of your conference.

ADDF FUNDING PORTAL